BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Federal Trade Commission
Argus Health
Cerilliant
Baxter
Express Scripts
Dow
Merck
Moodys
Medtronic

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,791,127

« Back to Dashboard

Which drugs does patent 8,791,127 protect, and when does it expire?

Patent 8,791,127 protects SITAVIG and is included in one NDA.

This patent has twenty-six patent family members in twenty-four countries.
Summary for Patent: 8,791,127
Title:Mucosal bioadhesive slow release carrier for delivering active principles
Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
Inventor(s): Costantini; Dominique (Paris, FR), Lemarchand; Caroline (Paris, FR)
Assignee: BioAlliance Pharma (Paris, FR)
Application Number:13/943,504
Patent Claim Types:
see list of patent claims
Formulation; Use;

Drugs Protected by US Patent 8,791,127

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Epi Hlth SITAVIG acyclovir TABLET;BUCCAL 203791-001 Apr 12, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF HERPES LABIALIS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,791,127

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06290480Mar 24, 2006

Non-Orange Book US Patents Family Members for Patent 8,791,127

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,211,466 Mucosal bioadhesive slow release carrier for delivering active principles ➤ Subscribe
8,747,896 Mucosal bioadhesive slow release carrier for delivering active principles ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,791,127

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 101335185 ➤ Subscribe
South Korea 20090010958 ➤ Subscribe
Japan 5242548 ➤ Subscribe
Japan 2009531411 ➤ Subscribe
Israel 193987 ➤ Subscribe
Croatia P20100039 ➤ Subscribe
Spain 2335712 ➤ Subscribe
Hong Kong 1121692 ➤ Subscribe
European Patent Office 2216017 ➤ Subscribe
European Patent Office 1998750 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Argus Health
Novartis
Johnson and Johnson
UBS
Cipla
Daiichi Sankyo
Julphar
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot